Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imelciment
- Development stage
- Phase 1
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Imelciment (REGN9035) is a monoclonal antibody developed by Regeneron Pharmaceuticals as an antagonist of natriuretic peptide receptor 1 (NPRA, also known as NPR1). It is designed to act as a reversal agent for REGN5381, an NPR1 agonist antibody. Imelciment binds to and inhibits NPRA, thereby reversing the acute hemodynamic effects induced by REGN5381. The drug has been investigated primarily for cardiovascular indications such as heart failure and hypertension. Its mechanism involves blocking the action of natriuretic peptides at their receptor, potentially modulating blood pressure and cardiac function[2][7][1].
- Brand names
- imelciment
- Other names
- anti-REGN5381 antibodyanti-REGN-5381 antibodyanti-REGN 5381 antibody
02
Targets
NPR1 (Natriuretic peptide receptor 1)
Beyond the preview
Go deeper on imelciment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imelciment.